



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

16th May 2022

To

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Outcome of the Board Meeting

We wish to inform you that a meeting of the Board of Directors of the Company was held today i.e. 16th May, 2022 and inter alia, transacted the following business:

1. Intimation under Listing and Disclosure Requirements Regulations, 2015 (LODR)

Pursuant to the Regulation 33 of LODR the following documents are enclosed

- Approved Audited Financial Results (Standalone and Consolidated) for the quarter & year ended 31st March 2022
- Auditors Report for the year ended 31st March 2022
- Statement of Assets and Liabilities
- Certificate for unmodified opinion

2. Dividend

The Board has recommended a dividend of Rs. 90/- (including special dividend of Rs. 60) per equity share on face value of Rs.10 each for the year ended 31st March 2022, subject to approval of members at 97th Annual General Meeting to be held on Tuesday, 26th July, 2022.

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, 8th July, 2022 as the Record Date for determining entitlement of members to final dividend for the financial year ended 31st March, 2022. The dividend, if approved by the members will be paid on or after Wednesday, 27th July, 2022.

3. Annual General Meeting

The Ninety Seventh Annual General Meeting will held on Tuesday, 26th July, 2022, through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India.

4. Re-appointment of Statutory Auditors

Pursuant to Regulation 30(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Audit Committee of the Company, the Board has, at its meeting held today, recommended the re-appointment of Deloitte Haskins and Sells LLP, Chartered Accountants (Firm Registration No.117366W/W-100018) as the statutory auditors of the Company for a second term to hold the office for a further period of 5 (five) consecutive years from the conclusion of the 97th Annual General Meeting of the Company scheduled to be held in the year 2022 till the conclusion of the 102nd Annual General Meeting to be held in the year 2027, subject to the approval of the shareholders of the Company.

5. **Appointment of Independent Director**

Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, we wish to inform you that Board of Directors of the Company at its meeting held today has appointed as Mr. Manu Anand (DIN:00396716) an Additional Independent Director of the Company for a term of five years w.e.f. from 16th May 2022. Mr. Manu Anand is not related to any of the existing Directors of the Company and he is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority. A brief profile is attached as Annexure A

The Meeting of the Board of Directors of the Company commenced at 01.15 p.m. and concluded at 04.30 p.m.

Thanking you,

Yours faithfully
For **GlaxoSmithKline Pharmaceuticals Limited**



Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl: a. a.